, Volume 44, Issue 5, pp 720–727 | Cite as

Use of Plasma Volume Expanders in Myocardial Revascularisation

  • John H. Lacy
  • Creighton B. Wright
Practical Therapeutics


The optimal solution for priming cardiopulmonary bypass machines and for postoperative resuscitation following myocardial revascularisation should be inexpensive, free of risk of transmitting disease, and free of other detrimental side effects. Colloid solutions are preferred over crystalloid solutions because of elevations in extracellular sodium and water that occur with cardiopulmonary bypass.

Albumin, plasma protein solution, hetastarch (hydroxyethyl starch) and dextran are available for use if blood is not necessary and mediastinal blood is not available. Hetastarch is associated with a lower risk of bleeding and less risk of allergic reaction than dextran, and its cost is substantially less than that of albumin. However, high doses increase the risk of bleeding complications.


Dextran Cardiopulmonary Bypass Hydroxyethyl Starch Myocardial Revascularisation Colloid Osmotic Pressure 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Aberg M, Hedner U, Bergentz SE. Effect of dextran on factor VIII (antihemophilic factor) and platelet function. Annals of Surgery 189: 243–247, 1977CrossRefGoogle Scholar
  2. Alving BM, Hojima Y, Pisano JJ, Mason BL, Finlayson JS. Hypotension associated with prekallikrein activator (Hagemon-factor fragments) in plasma protein fraction. New England Journal of Medicine 299: 66–70, 1978PubMedCrossRefGoogle Scholar
  3. Belcher P, Lennox SG. Avoidance of blood transfusion in coronary artery surgery: a trial of hydroxyethyl starch. Annals of Thoracic Surgery 37: 674–679, 1982Google Scholar
  4. Bland JHL, Laver MB, Lowenstein E. Vasodilator effect of commercial 5% plasma protein fraction solutions. Journal of the American Medical Association 224: 1721–1724, 1973PubMedCrossRefGoogle Scholar
  5. Damon L, Adams M, Stricher RB, Ries C. Intracranial bleeding during treatment with hydroxyethyl starch. New England Journal of Medicine 317: 964–965, 1987PubMedGoogle Scholar
  6. Diehl JT, Lester JL, Cosgrove DM. Clinical comparison of hetastarch and albumin in postoperative cardiac patients. Annals of Thoracic Surgery 34: 674–679, 1982PubMedCrossRefGoogle Scholar
  7. Falk JL, Rackon EC, Astiz ME, Weil MH. Effects of hetastarch and albumin on coagulation in patients with septic shock. Journal of Clinical Pharmacology 28: 412–415, 1988PubMedGoogle Scholar
  8. Gallagher JD, Moore RA, Kerns D, Jose AB, Clark DL, et al. Effects of colloid and crystalloid administration on pulmonary extravascular water in the postoperative period after coronary artery bypass grafting. Anesthesia and Analgesia 64: 753–758, 1985PubMedGoogle Scholar
  9. Hulse JD, Yacobi A. Hetastarch: An overviewing of the colloid and its metabolism. Drug Intelligence and Clinical Pharmacology 17: 334–34, 1983Google Scholar
  10. Khosropour R, Lackner F, Steinbereithner K, Watzek C, Piza F, et al. Comparison of effects of hydroxyethyl starch (HES200/ 0.5) administered pre-and postoperative in vascular surgery with dextran 40 (60). Anaesthesist 29: 616–622, 1980PubMedGoogle Scholar
  11. Kirklin JW, Kirklin JK, Lell WA. Cardiopulmonary bypass for cardiac surgery. In Sabiston DC & Spencer FC (Eds) Gibbon’s surgery of the chest, 4th ed., pp. 909–925, WB Saunders, Philadelphia, 1983Google Scholar
  12. Kirklin JK, Lell WA, Kouchoukos NT. Hydroxyethyl starch verses albumin for colloid infusions following cardiopulmonary bypass in patients undergoing myocardial revascularization. Annals of Thoracic Surgery 37: 40–46, 1984PubMedCrossRefGoogle Scholar
  13. Kohler H, Kirch W, Horstmann HJ. Hydroxyethyl starch-induced macroamylasemia. International Journal of Clinical Pharmacology 15: 428–431, 1977Google Scholar
  14. Kohler H, Zschiedrich H, Classen R, Linfante A, Gamm H. The effects of 500ml 10% hydroxyethyl starch 100/0.5 and 10% dextran 40 on blood volume, colloid osmotic pressure, and renal function in normal human volunteers. Anaesthetist 31: 61–67, 1982Google Scholar
  15. Lamke LO, Liljedahl SO. Plasma volume changes after infusion of various plasma expanders. Resuscitation 5: 93–102, 1976PubMedCrossRefGoogle Scholar
  16. Lee WH Jr, Rubin JW, Huggins MP. Clinical evaluation of priming solutions for pump oxygenator perfusion. Annals of Thoracic Surgery 19: 529–536, 1975PubMedCrossRefGoogle Scholar
  17. Lewis JH, Szeto ILF, Bayer WL, Takaori M, Safer D. Severe hemodilution with hydroxyethyl starch and dextrans. Archives of Surgery 93: 941–950, 1966PubMedCrossRefGoogle Scholar
  18. London MJ, Ho JS, Triedman JK, Verrier ED. Mongano DT, et al. A randomized clinical trial of 10% pentastarch (low molecular weight hydroxyethyl starch) versus 5% albumin for plasma volume expansion after cardiac operations. Journal of Thoracic and Cardiovacular Surgery 97: 785–97, 1989Google Scholar
  19. Long DM Jr, Sanchez L, Varco RL, Lillehei CW. The use of low molecular weight dextran and serum albumin as plasma expanders in extracorporeal circulation. Surgery 50: 12–28, 1961PubMedGoogle Scholar
  20. Lutz H, Georgieff M. Effects and side effects of colloid plasma substitutes compared to albumin. Current Studies of Hematology and Blood Transfusion 53: 145–154, 1986Google Scholar
  21. Metcalf W, Dargan EL, Hehre EJ, Levitsky S, Dibuono TJ. Clinical physiological Characterization of a new dextran. Surgery Gynecology and Obstetrics 115: 199–206, 1962Google Scholar
  22. Moggio RA, Chan C, Somberg ED, Praeger PI, Reed GE, et al. Hemodynamic comparison of albumin and hydroxyethyl starch in postoperative cardiac surgery patients. Critical Care Medicine 11: 943–945, 1983PubMedCrossRefGoogle Scholar
  23. Munsch CM, MacIntyre E, Machin SJ, Mackie IJ, Treasure T. Hydroxyethyl starch: an alternative to plasma for postoperative volume expansion after cardiac surgery. British Journal of Surgery 75: 675–678, 1988PubMedCrossRefGoogle Scholar
  24. Olinger GN, Werner PH, Bonchek LI, Boerboom LE. Vasodilator effects of sodium acetate in the pooled protein fraction. Annals of Surgery 190: 305–311, 1979PubMedCrossRefGoogle Scholar
  25. Pacifico AD, Digerness S, Kirklin JW. Acute alterations of body composition after open cardiac operations. Circulation 41: 331–341, 1970PubMedCrossRefGoogle Scholar
  26. Packman MA, Evans G, Glynn MF, Mustard JF. The effect of plasma proteins on the interaction of platelets with glass surfaces. Journal of Laboratory and Clinical Medicine 73: 686–697, 1969Google Scholar
  27. Palanzo DA, Parr GVS, Bull AP, Williams DR, O’Neill MJ, et al. Hetastarch as a prime for cardiopulmonary bypass. Annals of Thoracic Surgery 34: 680–683, 1982PubMedCrossRefGoogle Scholar
  28. Porter SS, Goldberg RJ. Intraoperative allergic reactions to hydroxyethyl starch: a report of two cases. Canadian Anaesthetists’ Society Journal 33: 394–398, 1986PubMedCrossRefGoogle Scholar
  29. Ring J, Messmer K. Incidence and severity of anaphylactoid reactions to colloid volume substitutes. Lancet 1: 466–469, 1977PubMedCrossRefGoogle Scholar
  30. Saddler JM, Horsey PF. The new generation gelatins: A review of their history, manufacture and properties. Anaesthesia 42: 998–1004, 1987PubMedCrossRefGoogle Scholar
  31. Sade RM, Stroud MR, Crawford FA Jr, Kratz JM, Dearing JP, et al. A prospective randomized study of hydroxyethyl starch, albumin, and lactated Ringer’s solution as priming fluid for cardiopulmonary bypass. Journal of Thoracic and Cardiovascular Surgery 89: 713–722, 1985PubMedGoogle Scholar
  32. Saunders CR, Carlisle L, Bick RL. Hydroyethyl starch verses albumin in cardiopulmonary bypass prime solutions. Annals of Thoracic Surgery 36: 532–539, 1983PubMedCrossRefGoogle Scholar
  33. Shutney C, Deepika K, Militello PR, Majerus TC, Dawson B. Efficacy of hetastarch in the resuscitation of patients with multisystem trauma and shock. Archives of Surgery 118: 804–809, 1983CrossRefGoogle Scholar
  34. Strauss RG, Stansfield C, Henriksen RA, Villhauer PG. Pentastarch may cause fewer adverse effects on coagulation than hetastarch. Transfusion 28: 257–260, 1988PubMedCrossRefGoogle Scholar
  35. Strauss RG, Stump DG, Henrikson RA, Saunders R. Effects of hydroxyethyl starch on fibrinogen, fibrin clot formation, and fibrinolysis. Transfusion 25: 230–234, 1985PubMedCrossRefGoogle Scholar
  36. Stump DC, Strauss RG, Henrikson RA, Petersen RE, Saudners R. Effects of hydroxyethyl strch on blood coagulation, particularly factor VIII. Transfusion 25: 349–354, 1985PubMedCrossRefGoogle Scholar
  37. Symington BE. Hetastarch and bleeding complications. Annals of Internal Medicine 105: 627–628, 1986PubMedGoogle Scholar
  38. Thompson WL. Rational use of albumin and plasma substitutes. The Johns Hopkins Medical Journal 136: 220–225, 1975PubMedGoogle Scholar
  39. Thompson WL, Britton JJ, Walton RP. Persistence of starch derivatives and dextran when infused after hemorrhage. Journal of Pharmacology and Experimental Therapeutics 136: 126–132, 1962Google Scholar
  40. Verska JJ, Ludington LG, Brewer LA. A comparative study of cardiopulmonary bypass with nonblood and blood prime. Annals of Thoracic Surgery 18: 72–80, 1974PubMedCrossRefGoogle Scholar
  41. Yacobi A, Stoll RG, Sum Cy, Lai CM, Gupta SD, et al. Pharmocokinetics of hydroxyethyl starch in normal subjects. Journal of Clinical Pharmacology 22: 206–212, 1982PubMedGoogle Scholar
  42. Zuhdi N, McCollough B, Carey J, Kriger C, Greer A. Hypothermic perfusion for open-heart surgical procedures: report on the use of a heart-lung machine primed with 5% dextrose in water inducing hemodilution. Journal of the International College of Surgeons 35: 319–326, 1961PubMedGoogle Scholar

Copyright information

© Adis International Limited 1992

Authors and Affiliations

  • John H. Lacy
    • 1
  • Creighton B. Wright
    • 1
  1. 1.Department of SurgeryThe Jewish Hospital of CincinnatiCincinnatiUSA

Personalised recommendations